The Treatment of Addictions in the Course of Care in Oncology: an Inventory of Fixtures Among Paramedical Professionals (PREFACE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03706937|
Recruitment Status : Completed
First Posted : October 16, 2018
Last Update Posted : July 23, 2019
|Condition or disease||Intervention/treatment|
|Paramedical Professional||Other: Semi directive interview|
|Study Type :||Observational|
|Actual Enrollment :||15 participants|
|Official Title:||The Treatment of Addictions in the Course of Care in Oncology: an Inventory of Fixtures Among Paramedical Professionals|
|Actual Study Start Date :||October 1, 2018|
|Actual Primary Completion Date :||December 20, 2018|
|Actual Study Completion Date :||December 31, 2018|
Paramedical professionals of the Lucien Neuwirth Cancer Institute
Other: Semi directive interview
Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
- Quantification of addiction managements [ Time Frame: 3 months ]We therefore wish to carry out descriptive qualitative research in the Lucien Neuwirth Oncology Institute in order to try to define the management of addictions in the oncology care course. In a first time, number of addiction managements will be reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03706937
|Institut de Cancérologie Lucien Neuwirth|
|Saint-Priest-en-Jarez, France, 42270|
|Study Director:||Elise Verot||Institut de Cancérologie Lucien Neuwirth|